Stocktoria
Elanco Animal Health Inc ELAN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2018-09-20
Chart by TradingView
5/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$12.3B
P / S2.6×
P / B1.9×
P / FCF43.2×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B |
| Gross profit | $2.6B | $2.4B | $2.5B | — | — |
| Net income | -$232.0M | $338.0M | -$1.2B | -$78.0M | -$483.0M |
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M |
| Free cash flow | $284.0M | $394.0M | $131.0M | $281.0M | $324.0M |
| Total assets | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B |
| Total liabilities | $6.8B | $6.5B | $8.1B | $8.2B | $9.0B |
| Shareholders' equity | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B |
| Ratios | |||||
| Gross margin | 55.0% | 54.9% | 56.3% | — | — |
| Net margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% |
| FCF margin | 6.0% | 8.9% | 3.0% | 6.4% | 6.8% |
| Return on assets | -1.7% | 2.7% | -8.6% | -0.5% | -2.9% |
| Return on equity | -3.5% | 5.5% | -19.8% | -1.1% | -6.4% |
| Debt / equity | 0.57× | 0.71× | 0.92× | 0.80× | 0.84× |
| Current ratio | 2.17 | 2.44 | 2.75 | 1.93 | 1.99 |
| Revenue growth | 6.2% | 0.5% | 0.1% | -7.4% | 45.6% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Bridgewater Associates, LP | 86,190 | $2.1M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001739104 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.